Drug Discovery@nature.com 27 September 2013

TABLE OF CONTENTS 27 September 2013 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature Immunology  FOCUS ON MICROBIOTA This series of specially commissioned articles discuss the reciprocal regulation between the host immune system and commensal microbiota, the dynamic interactions between commensals and pathogens, and emerging information on how resident viruses might influence immune homeostasis.    News Top Biotechs to tap into Horizon 2020's $93 billion doi:10.1038/nbt0913-779 First public-private partnerships announced for the EU's 7-year $93 billion R&D programme, which is expected to begin next year. Full Text At the frontiers of lung fibrosis therapy doi:10.1038/nbt.2687 Despite recent failures, a flurry of activity in biotech and pharma is raising hopes that an effective drug for this fatal lung disease is on the way. Full Text Longer exclusivity sought for fixed-dose drug combinations doi:10.1038/nm0913-1075 Momentum is growing for combination drugs to gain up to five years of exclusivity against generic competition in the United States. Full Text First vaccines targeting 'cruise ship virus' sail into clinical trials doi:10.1038/nm0913-1076 Researchers are working to develop a vaccine against the highly contagious norovirus, with the lead candidate already tested in humans and at least two more contenders slated to enter clinical trials in the next couple of years. Full Text Analysis Top Inhibitor MEKanisms doi:10.1038/scibx.2013.981 Roche's Genentech unit has figured out why different MEK inhibitors exhibit varying efficacy against BRAF- or KRAS-driven cancers, which could help in the design of next-generation inhibitors with improved therapeutic indexes. Full Text The epigenetics pipeline doi:10.1038/nrd4091 Epigenetic alterations are found in a number of diseases. This analysis explores the different approaches that are being pursued to exploit the therapeutic potential of epigenetic targets, and provides an overview of the current epigenetics pipeline. Full Text Research Highlights Top HIV: Efficacy through BibNAbs doi:10.1038/nrd4109 Highly potent bispecific broadly neutralizing antibodies (bNAbs) against a broad range of HIV-1 strains show promise for passive immunization against virus. Full Text Cancer: Special delivery service doi:10.1038/nrd4107 Brain-penetrating nanocarriers loaded with dithiazanine iodide, an FDA-approved antihelminthic, could be used for treating glioblastoma multiforme. Full Text G protein-coupled receptors: A double attack on pain doi:10.1038/nrd4105 Ligands targeting a heteromer consisting of the μ-opioid receptor (the target of the analgesic morphine) and a second GPCR could overcome some of the limitations of morphine. Full Text Research & Reviews Top 50 years of hurdles and hope in anxiolytic drug discovery doi:10.1038/nrd4075 This Review analyses the major trends from a database of published preclinical studies on novel anxiolytic agents in the past 50 years, highlighting issues that may have hampered progress and offering recommendations to improve anxiolytic drug discovery. Full Text Disrupting proton dynamics and energy metabolism for novel cancer therapy doi:10.1038/nrc3579 This Review discusses the interplay among metabolism, hypoxia and pH regulation and whether pH-regulatory systems can be targeted for anticancer therapy. Full Text Mitogen-activated protein kinases in innate immunity doi:10.1038/nri3495 This Review summarizes our current understanding of the regulation and function of mitogen-activated protein kinases (MAPKs) in innate immunity, as well as the mechanisms by which pathogens manipulate MAPK activation and the potential of targeting MAPK pathways for the treatment of inflammatory diseases. Full Text Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond doi:10.1038/nrd4099 Sphingosine-1-phosphate (S1P) has a key role in the control of immune cell trafficking and is involved in disorders including cancer and inflammatory diseases. Here, Spiegel and colleagues discuss the ways in which S1P could be therapeutically targeted and highlight recent data from preclinical studies and clinical trials. Full Text Drug Discovery JOBS of the week Medical Director, Global Drug Safety Product Leader, NDD Merck Group PhD fellowship with focus on genetic interactions in response to drug treatment The Sommer Lab in the Department of Systems Biology at the Technical University of Denmark Drug Discovery Project Manager (Maternity Cover) Institute of Cancer Research (ICR) Research Associate in Multifunctional Nanoparticles for Simultaneous Imaging and Drug Delivery UCL Drug Discovery Opportunities at D. E. Shaw Research D. E. Shaw Research More Science jobs from Drug Discovery EVENT 2nd Annual Biomarkers in Drug Discovery & Development 09.10.13 Berlin, Germany More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.